NMN and NAD: understand the relationship

NAD, NAD+, NMN, NR, NAM. Five abbreviations, one family tree, and a shop shelf that sometimes treats them as one product. Let's work out who is related to whom, what people have actually measured, and where the story gets less tidy than the label.

The family story in one paragraph: NAD+ is a molecule that every cell uses to run its chemistry. NMN and NR are two of several ingredients the body can use to build more of it. In human trials, taking NMN or NR by mouth reliably raises NAD-related measurements in blood or cells, and the products were mostly well tolerated over weeks to months. Whether that turns into anything you would notice, or into healthier ageing, is much less settled: results on insulin sensitivity, muscle function and blood pressure are mixed, or come from small trials. Nobody has shown that either one extends human lifespan. In the EU, nicotinamide riboside chloride (NR) is an authorised novel food; NMN received a positive EFSA safety opinion in May 2026, but we found no authorisation for it as of 8 October 2026.

NAD+ in plain words

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, a helper molecule, that cells use in redox reactions, which makes it central to how they handle energy. It is also a required partner for other enzyme families, including sirtuins, CD38 and PARPs, and through them it touches DNA repair, chromatin remodelling, cell senescence and immune function. A 2021 review in Nature Reviews Molecular Cell Biology sets this out and adds that much remains to be learnt about whether restoring NAD+ in ageing humans is safe and beneficial (Covarrubias and colleagues).

That last point is the crux. Having a role in many processes is exactly why NAD+ gets a lot of attention. It is not, on its own, a reason to think more is better.

Does NAD+ fall with age? In blood, the picture is less tidy than the pitch

The sales pitch usually starts with "NAD+ declines as you age". The review above says tissue NAD+ declines with ageing in several model organisms, including rodents and humans. But the human blood data are less clear-cut than the pitch:

• A 2026 Nature Metabolism paper measured whole-blood NAD+ in seven independent human cohorts with a validated method. Levels stayed remarkably stable with age and across lifestyle interventions, but did change with NR supplementation. The authors say this challenges blood NAD+ as a biomarker of ageing (Trętowicz and colleagues).
• A 2022 community study of 1,518 adults (the Jidong community cohort) saw a lower level in people aged 40 to 49 than in those under 30, no continuing trend after 50 in the group as a whole, and higher levels in men than women. The authors saw the decline only in men (significant at 60 and over) and not in women (Yang and colleagues).
• A 2026 study of 529 community-dwelling Japanese adults aged 65 and over found lower whole-blood NAD+ in people with frailty. The link weakened after accounting for haematocrit, so blood-cell composition may be part of the story (Shida and colleagues).

Blood is not muscle or brain, so none of this proves tissue NAD+ doesn't fall. It does mean "your NAD+ is low, so top it up" is a hypothesis, not a measured fact for most people.

The family tree: who's who on the label

• Name: NAD+; What it is: The coenzyme itself; A useful fact: The thing everyone is trying to raise; clinics also offer it by infusion (see below)
• Name: Nicotinic acid; What it is: A form of niacin (vitamin B3); A useful fact: In one 2026 study, high-dose nicotinic acid raised blood NAD+ four to six times in healthy people, with the authors arguing for individual dosing and follow-up (Euro and colleagues)
• Name: Nicotinamide (NAM); What it is: The other form of niacin; A useful fact: For adults, an EU upper intake level of 900 mg a day was set in 2002, as cited by EFSA in 2026 (EFSA)
• Name: Nicotinamide riboside (NR); What it is: A niacin-related precursor; A useful fact: Authorised in the EU as "nicotinamide riboside chloride" (details below)
• Name: Nicotinamide mononucleotide (NMN); What it is: A precursor one chemical step beyond NR; A useful fact: EFSA describes a proposed route in which NMN is processed to NR outside cells and converted back to NMN inside them on the way to NAD. For regulation it is being assessed as a source of niacin, with a conversion factor of 1 to nicotinamide (EFSA, 2026)

That regulatory framing is a handy way to think about it. In EFSA's eyes, NMN is a vitamin-B3-type ingredient first. Any step from "it's a niacin source" to "it's an anti-ageing ingredient" is a separate claim that needs its own evidence.

What the human trials found

Here are five well-known trials, with who took part, what they took and who paid. They aren't comparable head to head: different people, doses and outcomes.

• Trial: Martens and colleagues, 2018; Who and how long: 30 healthy adults randomised, 24 completing, crossover with 6 weeks on each arm; What they took: NR, 1,000 mg a day; Result: Well tolerated and raised NAD+ metabolism; exploratory blood-pressure and arterial-stiffness findings flagged for future trials (Nat Commun); Funding and ties: NIH grants; the NR producer ChromaDex supplied study capsules and part of the funding
• Trial: Dollerup and colleagues, 2018; Who and how long: 40 obese, insulin-resistant men aged 40 to 70; 12 weeks; What they took: NR, 1,000 mg twice a day; Result: No improvement in insulin sensitivity, energy expenditure or body composition; no serious adverse events (AJCN); Funding and ties: Described as investigator-initiated
• Trial: Elhassan and colleagues, 2019; Who and how long: 12 older men; crossover, 21 days; What they took: NR, 1,000 mg a day; Result: Raised the muscle NAD+ metabolome and lowered some inflammatory markers, without changing mitochondrial energy output (Cell Rep); Funding and ties: ChromaDex supplied NR; one author holds patents licensed by ChromaDex and owns stock in it
• Trial: Yoshino and colleagues, 2021; Who and how long: 25 postmenopausal women with prediabetes who were overweight or obese (13 NMN, 12 placebo); 10 weeks; What they took: NMN, 250 mg a day; Result: Insulin-stimulated glucose disposal in muscle rose on NMN and did not change on placebo; body weight, blood pressure and blood glucose measures did not change, and muscle NAD+ itself did not change (Science); Funding and ties: NIH grants and others; one author receives part of patent-licensing fees from MetroBiotech and Teijin and another is an inventor on an NMN patent application; NMN from Oriental Yeast
• Trial: Igarashi and colleagues, 2022; Who and how long: 42 healthy older men randomised; 6 or 12 weeks; What they took: NMN, 250 mg a day; Result: Raised blood NAD+ and its metabolites; "nominally significant" gains in gait speed and left grip that the authors say need larger studies; no effect on body composition (npj Aging); Funding and ties: Funded and supplied with NMN by Mitsubishi Corporation Life Sciences, whose employees are among the authors. A supplier error meant 22 participants received the wrong supplement at week 6, so their week-12 data were excluded and 20 completed the 12-week analysis

Two systematic reviews give the wider picture. A 2026 review found 113 eligible studies, 33 of them in humans (28 randomised). In humans, oral NR and NMN consistently raised NAD-related metabolites and were generally well tolerated over weeks to months, but effects on functional, metabolic, vascular and other healthspan-related outcomes were "heterogeneous and often null or endpoint-specific". Its overall conclusion: clear biological activity, clinical effectiveness for anti-ageing and wellness still inconclusive (Gallagher and Emmanuel). A separate 2026 meta-analysis of 15 randomised trials of oral NMN, at 250 to 2,000 mg a day for 14 days to 24 weeks, found no clear increase in adverse events or liver enzymes and no effect on body weight, BMI, fasting glucose, HbA1c, blood lipids or systolic blood pressure. Diastolic blood pressure dipped slightly, a result the authors call preliminary (Yang and colleagues).

How to read all that? Raising a blood number is the easy, repeatable part. Moving something you would care about, like insulin sensitivity, grip strength or blood pressure, has happened in some small trials and not in others. Yoshino's muscle result is the most striking, and it comes from 25 women with a specific metabolic condition, not from healthy adults. And almost every trial listed has a funder or author with a commercial interest in a precursor, which is common in this field and worth knowing.

Trial doses versus EU limits: the awkward gap

Several trials used far more than the EU has assessed for food supplements. EU conditions for NR chloride are 300 mg a day for adults, and EFSA's 2026 NMN opinion assessed up to 300 mg a day. Martens and Elhassan used 1,000 mg of NR a day, Dollerup used 2,000 mg a day, and the NMN meta-analysis includes trials up to 2,000 mg a day. The two NMN trials above (Yoshino and Igarashi) used 250 mg a day, within the assessed range.

This is a comparison of numbers, not a recommendation. It means "the study found X at 1,000 mg" does not carry over to a 300 mg product, and nothing here is a dose for you.

Safety: what the trials and EFSA say

In the trials above and the NMN meta-analysis, short-term tolerability looked good. Those trials run from days to 24 weeks, so they say little about years of use.

EFSA's 2026 NMN opinion adds a regulator's view. It concluded NMN is safe under the proposed conditions, up to 300 mg a day in food supplements for adults, excluding pregnant and lactating women. Some details are worth knowing: the 300 mg corresponds to 109.7 mg of nicotinamide, around five times the adult reference intake for niacin but below the 900 mg upper level for nicotinamide. In a 90-day rat study, effects on reproductive organs were seen; EFSA judged the margin of exposure of 93 sufficient for the proposed use. The human bioavailability study it relied on was unpublished, and EFSA reported that it raised no safety concerns (EFSA).

If you take medicines, have a medical condition, or are pregnant or breastfeeding, talk to a pharmacist or doctor before taking any NAD precursor. Our page on supplements and medication lists useful questions to ask.

Rules in the EU, the Netherlands and the US (read on 8 October 2026)

NR in the EU. Nicotinamide riboside chloride was authorised as a novel food by Implementing Regulation (EU) 2020/16, authorised on 20 February 2020, for use in food supplements (Regulation 2020/16). Regulation (EU) 2022/1160 of 5 July 2022 sets the conditions: food supplements at 300 mg a day for adults excluding pregnant and lactating women, and 230 mg a day for pregnant and lactating women, with further conditions for some medical foods and meal replacements (Regulation 2022/1160). The entry says its data-protection period ended on 20 February 2025. Check the current consolidated version for newer amendments.

NMN in the EU. EFSA's opinion on β-NMN from EffePharm (Shanghai), adopted on 4 March 2026 and published in May 2026, is a safety opinion, not an authorisation. To be sold lawfully as a novel food, NMN needs a Commission implementing regulation adding it to the Union list. We found none as of 8 October 2026, and the Commission's page of ongoing applications, opened on the same date, still lists NMN entries as applications or a notification. The Official Journal could not be searched directly, so confirm in the Commission's Novel Food Status Catalogue before relying on this. In practice, a product sold as NMN is not covered by an authorisation we could find.

The Netherlands. EU novel-food law applies. No separate Dutch statement on NMN or NR turned up; the Dutch food authority (NVWA) is the place to check.

The US. According to a law-firm summary of two FDA letters dated 29 September 2025, FDA reversed its earlier position and concluded NMN is not excluded from the definition of a dietary supplement, because it was marketed as a supplement before it was authorised for drug investigation. It still counts as a new dietary ingredient, so companies must follow notification rules (Venable summary). US rules don't change what is allowed in the EU.

Laws change, so check current rules before buying.

Injections and IV NAD+: what evidence exists

Some clinics offer NAD+ by drip or injection.

• The 2026 systematic review above found no eligible outcome trials of intravenous or intramuscular NAD+ for anti-ageing or wellness. It found one non-randomised intravenous NMN study that mainly contributed short-term safety and biomarker information, plus an NAD+ infusion pilot that had no eligible clinical outcomes (Gallagher and Emmanuel).
• That infusion pilot, from 2019, gave NAD+ over 6 hours and found it was rapidly cleared from plasma; no rise in plasma NAD+ appeared until after 2 hours (Grant and colleagues).
• A 2026 retrospective review of records from a commercial clinic compared four days of 500 mg NAD+ or NR infusions. People receiving NAD+ reported moderate to severe gastrointestinal symptoms, faster heart rate and chest pressure during infusions; symptoms resolved when the infusion ended, and infusions took longer (97 minutes versus 37 for NR). It is a records review, not a trial (Reyna and colleagues).
• A 2026 narrative review concluded evidence on IV NAD+ is preliminary and insufficient to support routine clinical or wellness use, with reported adverse effects including nausea, cramping, flushing and chest discomfort, and a lack of long-term safety data (Alangari and colleagues).

Our position, which is editorial: oral findings can't be borrowed for an injection, and anything given into a vein or muscle is a medical procedure, not a supplement. If a clinic offers it, ask what trial evidence supports the benefit being advertised, who monitors you, and what happens if you feel unwell during an infusion.

Should you test your NAD+?

The 2026 blood-NAD+ work above found stable levels across ages in whole blood. A result from a consumer test is not a validated target to chase, and a company's "optimal range" is a marketing choice. If you test, ask what decision the number is meant to inform.

So what is the relationship between NMN and NAD?

NMN is one of several raw materials the body can use to make NAD+. Taking it by mouth does raise NAD-related measurements in people. That is where the strong evidence ends. For outcomes people care about, the human trials so far are small, mixed and often tied to precursor makers, and no trial shows longer life. For readers in the Netherlands, there is also a plain regulatory fact: NR has an EU authorisation with a 300 mg daily limit, while NMN has a positive safety opinion but no authorisation we could find.

That makes NMN one to watch rather than one to rush. What would move the story along: larger, longer trials with clear primary outcomes in healthy adults, funded independently of precursor makers, and an authorisation decision on NMN from the Commission.

Next reading: how to read supplement labels and Smart Supplements 101.

Written by Smart Supplements with AI assistance from the sources linked in the text. It has not been reviewed by a clinician.

Last updated: 12 October 2026

This article is for informational purposes only and is not intended as medical advice. Always consult a healthcare professional before starting any new supplement, especially if you take prescription medication.